7630-74-2

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydro-1,2-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline is used as a potential anti-cancer agent for its ability to inhibit the growth of various cancer cells. Its multifaceted mechanism of action, which includes DNA intercalation, topoisomerase inhibition, and microtubule disruption, makes it a valuable candidate for further research and development in cancer treatment.
Used in Cancer Research:
In the field of cancer research, 5,6-Dihydro-1,2-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline serves as a subject of study for understanding its anti-cancer properties and exploring its potential as a therapeutic agent. The ongoing research aims to elucidate the compound's mechanisms of action and to assess its efficacy and safety in treating different types of cancer.
Used in Drug Development:
5,6-Dihydro-1,2-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline is utilized in drug development as a lead compound for the creation of novel anti-cancer medications. Its unique properties and mechanisms of action provide a foundation for the design of new drugs that could potentially offer improved treatment options for cancer patients.
Used in Toxicology Studies:
In toxicology, 5,6-Dihydro-1,2-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline is employed in studies to evaluate its safety profile and potential side effects. Understanding the compound's toxicological properties is crucial for assessing its suitability as a therapeutic agent and for determining the appropriate dosages for clinical use.
Used in Drug Interaction Studies:
5,6-Dihydro-1,2-dimethoxy-6-methyl-4H-dibenzo[de,g]quinoline is also used in studies investigating its potential interactions with other drugs and compounds. This research is essential for identifying any synergistic or antagonistic effects that may influence the compound's therapeutic efficacy and safety in combination with other treatments.

Upstream product

• 5868-18-8 nuciferine 
• 55610-02-1 cepharadione B 
• 475-83-2 R-(-)-nuciferine 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 6275-29-2 N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide 
• 4721-98-6 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
• 101064-78-2 1-(6,7-dimethoxy-1-methylene-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one 
• 54750-04-8 nornuciferine 

Relevant academic research and scientific papers

THREE BIS-DEHYDROAPORPHINES FROM OXANDRA CF. MAJOR

The structures of urabaine, N-methylurabaine and N,N'-dimethylurabaine, three new 7,7'-bis-dehydroaporphine alkaloids from Oxandra cf. major, have been elucidated by spectroscopic analysis and synthesis. - Key Word Index: Oxandra cf. major; Annonaceae; 7,7'-bisdehydroaporphine alkaloids; urabaine.

Total Syntheses of Aporphine Alkaloids via Benzyne Chemistry: An Approach to the Formation of Aporphine Cores

Total syntheses of lysicamine, (±)-nuciferine, (±)-nornuciferine, (±)-zanthoxyphylline iodide, (±)-O-methylisothebaine, and (±)-trimethoxynoraporphine were accomplished by an approach that involves the formation of aporphine cores through reactions betwee

Synthesis and structure-Activity relationship of nuciferine derivatives as potential acetylcholinesterase inhibitors

Acetylcholinesterase inhibitors (AChEIs) are currently the best available pharmacotherapy for Alzheimer patients, but because of bioavailability issues, there is still great interest in discovering better AChEIs. The aporphine alkaloid is an important class of natural products, which shows diverse biological activity, such as acetylcholinesterase inhibitory activity. To find new lead AChEIs compounds, eight aporphine alkaloids were synthesized by O-dealkylation, N-dealkylation, and ring aromatization reactions using nuciferine as raw material. The anti-Acetylcholinesterase activity of synthesized compounds was measured using modified Ellman's method. The results showed that some synthesized compounds exhibited higher affinity to AChE than the parent compound nuciferine. Among these compounds, 1,2-dihydroxyaporphine (2) and dehydronuciferine (5) were the most active compounds (IC50 = 28 and 25 μg/mL, respectively). Preliminary analysis of structure-Activity relationships suggested that aromatization of the C ring, the presence of the alkoxyl group at C1 and the hydroxy group at C2 position as well as the alkyl substituent at the N atom were favorable to the acetylcholinesterase inhibition. Molecular docking was also applied to predict the binding modes of compounds 1, 2, and 9 into the huperzine A binding site of AChE.

The palladium(0) Suzuki cross-coupling reaction as the key step in the synthesis of aporphinoids

We report a flexible approach to the total synthesis of 4,5-dioxoaporphines based on the palladium(0) catalyzed Suzuki cross-coupling of phenylboronic acids with sterically hindered 2-bromo phenyl acetates or bromo phenyl acetamides, followed by sequential bicyclization of biarylacetamides promoted by oxalyl chloride/Lewis acid. The reduction of 4,5-dioxoaporphines provides a chemoselective entry to aporphines, dehydroaporphines and 4-hydroxy- dehydroaporphines. A three-steps total synthesis for (±)-O,O′- dimethylapomorphine from readily accessible precursors is also reported.